Shanghai Ruijin Hospital
Shanghai Ruijin Hospital
Shanghai, China5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Multicenter Validation of a Risk Prediction Model for MDRGNB Infection | Infections | Recruiting | Not stated | 2026-05-27 | NCT07603128 | |
| CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors | large B-cell lymphoma | Not yet recruiting | Phase 2 | 2024-08-22 | NCT06567366 | |
| CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-lymphoblastic lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2023-11-18 | NCT06136364 | |
| Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results | acute myeloid leukemia | Recruiting | Phase 2 | 2023-03-15 | NCT05736978 | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2023-03-15 | NCT05736965 |